Loading...
Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome
Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activ...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3511797/ https://ncbi.nlm.nih.gov/pubmed/22931129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1546-0096-10-30 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|